It’s vital that we continue to drive the development of novel therapies, so that myeloma patients can benefit from the most important advances in cancer treatment. We do this by investing directly in early-stage biopharma companies with promising technologies and conducting clinical trials that evaluate novel treatment approaches.
The MyDRUGSM clinical trial program is still enrolling patients at cancer centers throughout the United States that are part of the MMRC®. For help/assistance with questions please contact our Patient Navigation Center.